ARTICLE | Clinical News
ADL 8-2698: Phase II
November 22, 1999 8:00 AM UTC
In Phase I and II trials involving a total of 118 patients treated with ADL 8-2698, the compound statistically significantly reversed narcotic-induced slowing of upper and lower gut motility and const...